Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31 CHF | -0.32% | -1.58% | +14.82% |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
May. 22 | Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.04% | 15.02B | |
+17.84% | 41.07B | |
+24.16% | 22.65B | |
+19.95% | 14.14B | |
+52.52% | 12.09B | |
-0.05% | 6.79B | |
-10.97% | 6.91B | |
-8.87% | 5.73B | |
+15.28% | 5.59B | |
+4.00% | 4.82B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Transcript : Sandoz Group AG, Q1 2024 Sales/ Trading Statement Call, May 07, 2024